We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

113 hedge funds and large institutions have $515M invested in Albany Molecular Research Inc in 2014 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $6.15M | Put options by funds: $2.52M

95% more capital invested

Capital invested by funds: $264M → $515M (+$251M)

3% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 36

4% less funds holding

Funds holding: 118113 (-5)

18% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 28

Holders
113
Holders Change
-5
Holders Change %
-4.24%
% of All Funds
3.26%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.06%
New
23
Increased
37
Reduced
36
Closed
28
Calls
$6.15M
Puts
$2.52M
Net Calls
+$3.63M
Net Calls Change
+$3.46M
Name Holding Trade Value Shares
Change
Change in
Stake
VAM
1
Visium Asset Management
New York
$58.6M
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$48.9M +$55.6K +4,037 +0.2%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$31.2M -$15.9M -1,153,932 -41%
RA
4
Royce & Associates
New York
$25M -$936K -67,958 -5%
EWM
5
Evercore Wealth Management
New York
$24.8M -$427K -31,000 -2%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$23.4M +$171K +12,440 +1%
BFA
7
BlackRock Fund Advisors
California
$19.2M +$255K +18,488 +2%
Millennium Management
8
Millennium Management
New York
$19M +$13.3M +967,629 +1,774%
HM
9
HealthCor Management
New York
$16.7M +$12.4M +900,000 New
ACM
10
American Capital Management
New York
$16.7M -$643K -46,700 -5%
Allianz Asset Management
11
Allianz Asset Management
Germany
$16.4M +$1.06M +76,806 +10%
Vanguard Group
12
Vanguard Group
Pennsylvania
$14.1M -$5.93K -431 -0.1%
BIT
13
BlackRock Institutional Trust
California
$13.8M -$8.91M -646,766 -47%
Renaissance Technologies
14
Renaissance Technologies
New York
$13M +$2.53M +184,090 +36%
DCM
15
Decade Capital Management
New York
$12.1M +$8.95M +650,000 New
Morgan Stanley
16
Morgan Stanley
New York
$10.9M -$625K -45,373 -7%
BIM
17
Bogle Investment Management
Massachusetts
$9.74M +$7.21M +523,914 New
HVC
18
Healthcare Value Capital
New Jersey
$8.33M +$6.17M +448,200 New
RFC
19
Russell Frank Company
Washington
$7.73M +$3.95M +287,095 +147%
BCM
20
Bridgeway Capital Management
Texas
$7.62M -$35.4K -2,572 -0.6%
Invesco
21
Invesco
Georgia
$7.59M +$2.42M +176,069 +76%
NAM
22
Netols Asset Management
Wisconsin
$7.55M +$5.59M +406,332 New
State Street
23
State Street
Massachusetts
$6.38M +$28.2K +2,051 +0.6%
Northern Trust
24
Northern Trust
Illinois
$5.9M -$281K -20,434 -6%
JP Morgan Chase
25
JP Morgan Chase
New York
$4.39M -$1.61M -117,133 -33%

AMRI Hedge Fund Activity: Q1 2014 in Review

113 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q1 2014, worth a combined $515M — up 95% from $264M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of AMRI and 23 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 37 added.

The largest buyer was Millennium Management, adding an estimated $13.3M. The largest seller was Wellington Management Group, cutting an estimated $15.9M.

  • 113 institutional investors held Albany Molecular Research Inc (AMRI) as of Q1 2014, down from 118 in Q4 2013.
  • Funds reported $515M of Albany Molecular Research Inc stock for Q1 2014, up 95% quarter-over-quarter.
  • 23 funds opened new Albany Molecular Research Inc positions in Q1 2014 and 28 closed out, a net change of -5 holders.
  • The largest Albany Molecular Research Inc buyer in Q1 2014 was Millennium Management, an estimated $13.3M added.
  • The largest Albany Molecular Research Inc seller in Q1 2014 was Wellington Management Group, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2014.